Recent Company News

• 12:04 PM ET Jun 10, 2026
  

  Teva completes acquisition of Emalex Biosciences ($34.04, -0.41)

• 12:03 PM ET Jun 10, 2026
  

  Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

• 08:47 AM ET Jun 08, 2026
  

  Transcript Intelligence: Teva Pharmaceutical at Goldman Sachs Global Healthcare Conference ($34.19, 0.00)

• 08:07 AM ET Jun 08, 2026
  

  Teva Pharmaceutical presents new data on AUSTEDO and AUSTEDO XR ($34.19, 0.00)

• 08:01 AM ET Jun 08, 2026
  

  Teva's Data on AUSTEDO(R) (deutetrabenazine) tablets and AUSTEDO XR(R) (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

• 04:02 AM ET Jun 08, 2026
  

  FDA accepts Alvotech's BLA for AVT16 for review ($3.54, 0.00)

• 11:32 AM ET Jun 05, 2026
  

  Teva presents new data on AUSTEDO tablets and AUSTEDO XR extended-release tablets in Huntington's disease chorea ($34.88, +0.45)

• 11:29 AM ET Jun 05, 2026
  

  Teva Presents New Data on AUSTEDO(R) (deutetrabenazine) tablets and AUSTEDO XR(R) (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

• 08:55 AM ET Jun 04, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:31 AM ET Jun 04, 2026
  

  Teva Pharmaceutical announces launch of Eylea biosimilar ($32.83, 0.00)